Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dynavax Technologies Corporation

DVAX
Current price
10.87 USD +0.31 USD (+2.94%)
Last closed 10.56 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 1 382 219 520 USD
Yield for 12 month -23.29 %
1Y
3Y
5Y
10Y
15Y
DVAX
21.11.2021 - 28.11.2021

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California. Address: 2100 Powell Street, EmeryVille, CA, United States, 94608

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

25.75 USD

P/E ratio

150.8572

Dividend Yield

Current Year

+232 284 000 USD

Last Year

+722 683 000 USD

Current Quarter

+50 790 000 USD

Last Quarter

+55 596 000 USD

Current Year

+182 117 000 USD

Last Year

+460 530 000 USD

Current Quarter

+39 824 000 USD

Last Quarter

+46 907 000 USD

Key Figures DVAX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -16 719 000 USD
Operating Margin TTM -38.14 %
PE Ratio 150.8572
Return On Assets TTM -1.35 %
PEG Ratio
Return On Equity TTM 1.56 %
Wall Street Target Price 25.75 USD
Revenue TTM 236 148 992 USD
Book Value 4.73 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 8.2 %
Dividend Yield
Gross Profit TTM 448 218 000 USD
Earnings per share 0.07 USD
Diluted Eps TTM 0.07 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY -76.5 %
Profit Margin 3.9 %

Dividend Analytics DVAX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History DVAX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 10.11.2014
Dividend Date

Stock Valuation DVAX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 150.8572
Forward PE 400
Enterprise Value Revenue 4.5807
Price Sales TTM 6.6704
Enterprise Value EBITDA 110.0795
Price Book MRQ 2.4907

Financials DVAX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators DVAX

For 52 weeks

10.41 USD 15.15 USD
50 Day MA 11.46 USD
Shares Short Prior Month 22 064 100
200 Day MA 12.8 USD
Short Ratio 7.32
Shares Short 18 056 455
Short Percent 16.86 %

Dynamics of changes in the value of assets

S

STP

135.00 EUR Stef S. A. 0 (0%)
Detailed analytics
M

M6M

33.20 EUR Marcus & Millichap Inc 0 (0%)
Detailed analytics
8

8628

853.00 JPY Matsui Securities Co. Ltd. +0.01 (+0.12%)
Detailed analytics
0

0QF5

2.62 EUR bpost NV -0.05 (-1.69%)
Detailed analytics
4

4IH

37.20 EUR ICHOR HLDGS LTD DL-0001 0 (0%)
Detailed analytics